Pacira Pharmaceuticals: Positioned for Growth with NOPAIN Act and Innovative Therapies
Pacira Pharmaceuticals (PCRX) has received a new Buy rating from H.C. Wainwright analyst Douglas Tsao, driven by the NOPAIN Act and innovative therapies. The NOPAIN Act enhances Exparel's market potential, and approvals for nerve blocks and Vertex’s suzetrigine support opioid-free surgeries. Promising data from Pacira’s IL-1Ra gene therapy, PCRX-201, in osteoarthritis, and the Phase 2 ASCEND study, position Pacira for growth. Tsao's $38 price target is based on a DCF model. Needham also maintained a Buy rating with a $30 price target.
Pacira Pharmaceuticals (PCRX) has received a new Buy rating, initiated by H.C. Wainwright analyst, Douglas Tsao.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight Pacira Pharmaceuticals’ potential for growth and innovation. A key driver is the enactment of the NOPAIN Act, which eliminates barriers to accessing Exparel in surgical procedures, enhancing its market potential. Additionally, the approval for nerve blocks has improved Exparel’s clinical efficacy, aligning it more closely with anesthesiologists and reducing technique sensitivity.
Furthermore, the approval of Vertex’s suzetrigine complements Exparel, making opioid-free surgeries more attainable and likely to drive adoption. Tsao also notes the promising clinical data from Pacira’s IL-1Ra gene therapy, PCRX-201, in osteoarthritis, which could become a blockbuster product. This potential, along with the expected data from the Phase 2 ASCEND study, positions Pacira as an innovative biotech company, warranting a re-rating of its shares. The $38 price target is supported by a DCF model that accounts for the probability of success across Pacira’s portfolio.
In another report released on November 7, Needham also maintained a Buy rating on the stock with a $30.00 price target.
